• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W.L. GORE & ASSOCIATES BIFURCATED GORE-TEX STRETCH VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W.L. GORE & ASSOCIATES BIFURCATED GORE-TEX STRETCH VASCULAR GRAFT; PROSTHESIS, VASCULAR GRAFT Back to Search Results
Device Problem Patient-Device Incompatibility (2682)
Patient Problems Death (1802); Perforation of Vessels (2135); No Code Available (3191)
Event Date 10/07/2019
Event Type  Death  
Manufacturer Narrative
As the devices were not returned, no evaluation of the devices could be performed.(b)(4).
 
Event Description
The following publication was reviewed: frequency of perigraft hygroma after open aortic reconstruction.The objective of the study was to establish the incidence of and determine the risk factors associated with perigraft hygroma (pgh).Pgh is defined as a perigraft fluid collection of 30mm or greater in diameter with a radiodensity of 30 or fewer hounsfield units on computed tomography at a minimum of 3 postoperative months.Methods and results: patients who underwent open aortic reconstruction for either aneurysmal or occlusive disease between 2004 to 2018 using both eptfe and polyester grafts, and who had follow-up imaging 3 months or more after repair, were included.Of the 140 patients included in the study, 88 were treated with gore® surgical eptfe grafts.It was determined that pgh developed more frequently in patients with eptfe grafts (21/88) compared to those with polyester grafts.Of the 21 patients treated with an eptfe graft and who developed a subsequent pgh, 4 presented with pgh-related symptoms.All pghs developed after abdominal aortic aneurysm repairs.It was hypothesized that intrinsic graft porosity may also contribute to pgh formation.The following corrections to the article were reported by the corresponding author: there were 18 asymptomatic patients (not 17), none of whom underwent an intervention.There were 22 patients who developed pgh after being treated with a gore® device (not 21).All eptfe grafts were manufactured by w.L.Gore & associates (bifurcated gore-tex® stretch vascular graft).Of the patients treated with a gore® device, 58 were male and 30 were female.The mean age was 68.6 ± 10.2 years.It was concluded that pgh is a complication after open aortic reconstruction for aneurysmal disease, and that patient education and close surveillance is warranted.It was determined that patients who developed pgh had larger aneurysms, more often received eptfe grafts, had larger graft diameters, and had bifurcated grafts.Manufacturer's device modification is deemed necessary.Patient 4 - the last patient (previously implanted with a bifurcated gore-tex® stretch vascular graft 20 x 10) presented with an expanding 11.2-cm symptomatic pgh with vague abdominal pain and was admitted to hospital in preparation for surgical conversion.However, on admission day 3 he suffered a fatal hemorrhagic stroke before the pgh could be resected.
 
Manufacturer Narrative
As the patient did not undergo reintervention to treat the reported perigraft hygroma (pgh), this event will be considered non-reportable and this medwatch report will be retracted.
 
Manufacturer Narrative
Corrected data: g5.Combination product.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BIFURCATED GORE-TEX STRETCH VASCULAR GRAFT
Type of Device
PROSTHESIS, VASCULAR GRAFT
Manufacturer (Section D)
W.L. GORE & ASSOCIATES
flagstaff AZ
MDR Report Key9901793
MDR Text Key185656472
Report Number2017233-2020-00222
Device Sequence Number1
Product Code DSY
Combination Product (y/n)N
PMA/PMN Number
K904282
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Type of Report Initial,Followup,Followup
Report Date 07/09/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/30/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
MEDICATION: CREATININE; MEDICATION: CREATININE
Patient Outcome(s) Death; Hospitalization; Required Intervention;
Patient Age69 YR
-
-